Free Gastroenterology CME

In Current Treatment Options for C. difficile Infection and the Emergence of Hypervirulent Strains, a leading clinician discusses the increasing incidence and resistance of C. difficile, as well as hypervirulent strains, and evaluates current therapeutic agents for CDI in terms of safety, efficacy, and improvement of patient outcomes.

Upon successful completion of Current Treatment Options for C. difficile Infection and the Emergence of Hypervirulent Strains, you should be better able to:
• Assess the increasing incidence of C. difficile infection, as well as hypervirulent strains, in and outside of the hospital setting.
• Differentiate current treatment options for C. difficile infection in terms of safety, efficacy, and improvement of patient outcomes.

Target Audience: Gastroenterologists, infectious disease specialists, and other health care professionals involved in the treatment of patients with Clostridium difficile (C. difficile) infections.

In Guidelines and Strategies to Reduce C. difficile Infection Recurrence, a leading clinician discusses evidence-based guidelines for the management of Clostridium difficile infections (CDI) and evaluates therapeutic agents under investigation that may aid in treatment and reduce the occurrence of CDI.

Upon successful completion of Guidelines and Strategies to Reduce C. difficile Infection Recurrence, you should be better able to:
• Apply current evidence-based guidelines for the overall management of C. difficile infection.
• Incorporate treatment strategies that may reduce C. difficile infection recurrence, as well as antibiotic resistance.

Target Audience:
Gastroenterologists, infectious disease specialists, and other health care professionals involved in the treatment of patients with Clostridium difficile (C. difficile) infections.

Advances in Treating Metastatic Colorectal Cancer (CRC) discusses the diagnosis and treatment of metastatic colorectal cancer (mCRC).

By the end of Advances in Treating Metastatic Colorectal Cancer (CRC), you will be better able to:
• Describe present the current practice guideline recommendations with respect to colorectal cancer screening, including colonoscopy preparation, and apply them to patient cases
• Identify the treatment modalities currently available for management of mCRC and apply them to patient cases using evidence-based medicine
• Evaluate a treatment plan for a specific patient with mCRC to optimize safety, efficacy, and tolerability, suggesting modifications for improvement
• Describe the challenges and barriers to care associated with treating patients with mCRC

In order to receive credit from ScientiaCME, you must first establish a username and password.

Target Audience:
Medical oncologists, primary care physicians, pathologists, gastroenterologists, and managed care medical care directors; physicians assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with CRC.

Chronic Idiopathic Constipation (CIC) discusses conventional therapies: bulking agents, softeners, stimulants, osmotics; recent additions and investigational agents: prucalopride, plecanatide, linaclotide, lubiprostone; non-pharmacologic therapies and their place relative to pharmacotherapy: dietary, mechanical, behavioral, and surgical interventions; biofeedback; and clinical pearls and difficult-to-treat cases.

After reviewing Chronic Idiopathic Constipation (CIC), you will be able to:
• Describe the pathophysiology of chronic idiopathic constipation
• Describe the benefits and risks of pharmacotherapy for chronic idiopathic constipation and take them into account when formulating a treatment plan for different patients
• Formulate an evidence-based treatment plan for a variety of patients with chronic idiopathic constipation.
• Recommend therapy changes in patients with chronic idiopathic constipation who do not respond to a previously prescribed treatment

Target Audience:
Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in gastroenterology; and any other healthcare professionals with an interest in or who clinically encounter patients with chronic idiopathic constipation.

Carcinoid Syndrome: Updates in Pathophysiology, Diagnosis, and Treatment consists of a single lecture and discussion by Drs. Matthew H. Kulke and C. Metz.

After viewing Carcinoid Syndrome, you will be better able to:
• Summarize the cause of carcinoid syndrome
• Perform an appropriate workup and differential diagnosis from presenting symptoms
• Adopt evidence-based best practices in managing carcinoid syndrome, including strategies to address refractory or poorly controlled symptoms
• Evaluate safety and efficacy of current and emerging treatment approaches for carcinoid syndrome

Target Audiences:
This program is intended for US-based medical oncologists, endocrinologists and gastroenterologists, as well as oncology physician assistants, nurse practitioners, and nurses involved in the diagnosis and management of carcinoid tumors and carcinoid syndrome.

Inflammatory bowel disease (IBD) is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are Crohn’s Disease and ulcerative colitis, the former of which affects any area of the alimentary canal.

After reviewing Crohn’s Disease: Therapeutic Updates, Barriers to Care, and Emerging Therapies, you will be better able to:
• Describe the strengths and weaknesses of present and emerging diagnostic techniques, where applicable in Crohn’s disease.
• Describe strengths of different professional organizations’ guidance in Crohn’s disease diagnosis and treatment guidelines
• Describe emerging therapies in the treatment of Crohn’s disease.
• Describe barriers to care in the treatment of Crohn’s disease and suggest ways to ameliorate them.
• Identify the present treatment options currently available for management of Crohn’s disease and apply them to patient cases using evidence-based medicine.

Target Audience:
Healthcare professionals specializing in: gastroenterology, internal medicine, or those who otherwise commonly care for patients with Crohn’s disease.

This course contains two courses:
• Crohn’s Disease: Therapeutic Updates, Barriers to Care, and Emerging Therapies (1 hr CME)
• Inflammatory Bowel Disease (IBD): A Global Approach to Quality Management and Barriers to Care in an Era of Resource Consciousness(1.25 hr CME)

In order to get credit from ScientiaCME, you must first establish a username and password.

Target Audience:
Healthcare professionals specializing in colon and rectal surgery, family medicine, internal medicine, gastroenterology, oncology, pain management, palliative care, primary care, proctology, and other clinicians who treat patients suffering from gastrointestinal disorders.

This free online CME course highlights Irritable bowel syndrome (IBS) including causes, diagnosis, best treatment, and more.

Topics covered in this course include:

• IBS Epidemiology: prevalence/incidence in North America/globally, by age/sex
• Clinical features and diagnostic criteria of IBS-C
• Treatment of IBS-C
• IBS-C Patient case(s)

After completing this course, you will better be able to:

• Describe what is known about the etiology of IBS-C and its impact on patient clinical presentation
• Identify symptoms of IBS-C, describe their role in the diagnosis of the disorder, and list* any applicable lab and/or imaging studies that play a role in IBS-C diagnosis
• Evaluate treatments plans for patients with IBS-C and suggest appropriate therapies, where applicable, based on individual presentations
• Describe present and emerging drug therapies for management of IBS-C and apply them to patient cases
• Describe clinical and logistical challenges associated with treating and educating patients with IBS-C

Target audience: Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in gastroenterology; and any other healthcare professionals with an interest in or who clinically encounter patients with IBS-C.